Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Putting the Focus on p53 in Multiple Myeloma

March 7th 2013

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.

Dr. Zelenetz on Treating Hematologic Malignancies

March 6th 2013

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, describes challenges and emerging treatment approaches for patients with hematologic malignancies.

Dr. Landgren on Maintenance Therapy in Myeloma

February 25th 2013

Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the pros and cons of maintenance therapy for patients with myeloma.

Pomalidomide Approved for Relapsed or Refractory Multiple Myeloma

February 8th 2013

The FDA announced the approval of pomalidomide for the treatment of multiple myeloma after patients have relapsed or become refractory to other cancer drugs.

Dr. Berenson on Pomalidomide Plus Doxil in Multiple Myeloma

February 6th 2013

James R. Berenson, MD, discusses a phase I/II study of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma.

Dr. Jagannath on Life Expectancy in Myeloma

January 22nd 2013

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Dr. Brian Durie on Novel Therapies in Multiple Myeloma

January 15th 2013

Brian G. M. Durie, MD, Cedars-Sinai Medical Center, Senior Advisor, Hematologic Malignancies, National Program Director, Multiple Myeloma and Related Disorders for Aptium Oncology, discusses novel therapies for multiple myeloma.

Emerging Agents in Multiple Myeloma: An Overview

January 2nd 2013

More potent versions of existing therapies are currently under development and showing considerable promise in early clinical trials for patients with multiple myeloma.

Dr. Jagannath on Pomalidomide in Multiple Myeloma

December 21st 2012

Sundar Jagannath, MD, discusses the use of pomalidomide (POM) in relapsed or refractory multiple myeloma.

Pomalidomide Labeled an Advance in Multiple Myeloma

December 10th 2012

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

MLN9708 May be Alternative to Bortezomib in Multiple Myeloma

December 10th 2012

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.

Dr. Kumar on Managing Toxicities in the MLN9708 Study

December 9th 2012

Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, talks about managing toxicities in the MLN9708 study.

Pomalidomide Meets Primary PFS Endpoint

November 20th 2012

A data safety monitoring board (DSMB) has found that a phase III study of pomalidomide, an oral immunomodulatory agent, met its primary endpoint by demonstrating a significant improvement in progression-free survival for patients with multiple myeloma (MM).

Overcoming Genetic Transformation in Multiple Myeloma

November 6th 2012

The goal in treating newly diagnosed multiple myeloma is to achieve deep remission and prevent relapse, which is best achieved by targeted combination therapy very early in the course of disease.

Detecting Bone Disease in Multiple Myeloma Patients

October 16th 2012

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

September 12th 2012

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Bisphosphonates Remain Mainstays in Managing Bone Disease: Development of New Agents Is Continuing

September 5th 2012

Researchers have identified more than a dozen pathways and factors involving bone disease in patients with multiple myeloma who are at the highest risk of developing complications.

Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

August 31st 2012

Lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

August 2nd 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Researchers Share Honor for Bortezomib Discovery

July 27th 2012

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.